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Abstract: Measurements in clinical laboratories pro-
duce results needed in the diagnosis and monitoring of 
patients. These results are always characterized by some 
uncertainty. What quality is needed and what measure-
ment errors can be tolerated without jeopardizing patient 
safety should therefore be defined and specified for each 
analyte having clinical use. When these specifications are 
defined, the total examination process will be “fit for pur-
pose” and the laboratory professionals should then set up 
rules to control the measuring systems to ensure they per-
form within specifications. The laboratory community has 
used different models to set performance specifications 
(PS). Recently, it was felt that there was a need to revisit 
different models and, at the same time, to emphasize the 
presuppositions for using the different models. Therefore, 
in 2014 the European Federation of Clinical Chemistry and 
Laboratory Medicine (EFLM) organized a Strategic Confer-
ence in Milan. It was felt that there was a need for more 
detailed discussions on, for instance, PS for EQAS, which 
measurands should use which models to set PS and how 
to set PS for the extra-analytical phases. There was also a 
need to critically evaluate the quality of data on biologi-
cal variation studies and further discussing the use of the 
total error (TE) concept. Consequently, EFLM established 
five Task Finish Groups (TFGs) to address each of these 
topics. The TFGs are finishing their activity on 2017 and 
the content of this paper includes deliverables from these 
groups.
Keywords: biological variation; outcome; performance 
specifications.
Introduction
Performance specifications (PS) in laboratory medicine 
should ideally identify criteria that specify (in numerical 
terms) the quality required for laboratory test informa-
tion that can satisfy clinical needs for improving patients’ 
outcomes. Measurement uncertainty should in principle 
be within limits based on medical relevance making the 
results clinically acceptable and reliable for clinical deci-
sion-making and patient management [1]. If PS are not 
objectively defined and fulfilled, there is a risk of letting 
the variation in laboratory result overwhelm the clinical 
information supplied, even causing negative effects on 
patients’ outcomes [2, 3]. What degree of quality is needed 
to guarantee patient safety should therefore be precisely 
defined and specified for each analyte.
The debate focusing on how these limits should be 
defined, in order to answer the essential question about 
what amount of medical harm due to measurement error 
is acceptable to let go undetected, started many years ago 
[4]. In 1999, this was addressed in the organization of the 
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IFCC-International Union of Pure and Applied Chemistry 
(IUPAC) conference in Stockholm, where a hierarchy of 
sources for deriving the PS of laboratory measurements 
was established for the first time [5]. However, in a review 
of progress made in the 10 years following the conference, 
two of the organizers recognized challenges in the practi-
cal implementation of concepts and the need to reappraise 
the topic by simplifying the approaches and encompass-
ing further aspects, such as extra-analytical phases [6]. 
In consequence, the Strategic Conference “Defining Ana-
lytical Performance Goals – 15 years after the Stockholm 
Conference” was organized in Milan on November 2014 
by the European Federation for Clinical Chemistry and 
Laboratory Medicine (EFLM) to investigate to what extent 
the advocated hierarchy was still valid or if it has to be 
changed or expanded [7].
The Milan Strategic Conference
Although many of the ideas established in 1999  were 
supported, in the Milan conference the models for PS 
were based on three completely different theoretical 
frameworks (Table 1) [8]. Accordingly, the recommended 
approaches for defining PS should preferentially be 
based on the effect of measurement performance on clini-
cal outcome or on the biological variation of the meas-
urand. If PS based on these models could not be made, 
state-of-the-art could be used. Importantly, it should be 
noted that these three models use different principles and 
do not necessarily constitute a hierarchy. An important 
innovative aspect of the new consensus is the recognition 
that some models are better suited for certain measur-
ands than for others; the attention is therefore primarily 
directed towards the measurand and its biological and 
clinical characteristics [9]. Another novel aspect is the 
focus on the quality of the information. Independent of 
the model, high quality studies or data must be available. 
For instance, for many decades biological variability has 
been promoted as a source of analytical PS. This can be a 
good and usable model for many measurands, but it must 
be underlined that studies and papers with information 
about biological variation have to be critically appraised 
before they can be used to set PS [10–12]. The possibility to 
elaborate specifications at different levels of quality (i.e. 
minimum, desirable and optimum) to move, in case, from 
desirable to minimum PS is also an option (Figure 1). This 
will also make it possible for in vitro diagnostics (IVD) 
manufacturers to work for improving the quality of assay 
performance. In general, proposed PS should always be 
accompanied by a statement of the rationale, the source 
and the quality of the evidence behind the recommenda-
tion, together with the suggested application [8].
Another feature of the Milan conference is the concept 
that the application of the analytical PS can be modulated 
depending on its use. During the conference, Braga et al. 
[13] described for the first time the rationale behind the 
definition of recommended limits for combined measure-
ment uncertainty across the entire metrological traceabil-
ity chain. In comparison with the traditional approach, 
they turned the problem upside down, focusing first on 
the PS for combined uncertainty associated with patient 
results and recommending that the higher order refer-
ences should display uncertainty at most equal to 1/3 of 
these PS. Similarly, criteria for IVD manufacturers that can 
be achieved for their calibrators were defined in order to 
leave enough uncertainty budget for the individual labo-
ratories to produce clinically acceptable results on clinical 
samples [14]. Individual laboratories who provide patient 
results have of course a central role in correctly defining 
PS to be applied in daily practice. Recent examples in the 
Table 1: Models to be used for defining performance specifications 
according to the 2014 Milan Strategic Conference. 
Model 1: Based on the effect of test performance on clinical 
outcomes
 a.  Based on direct outcome studies – investigating the impact of 
performance of the test on clinical outcomes;
 b.  Based on indirect outcome studies – investigating the impact of 
performance of the test on clinical classifications or decisions 
and thereby on the probability of patient outcomes, e.g. by 
simulation or decision analysis
Model 2: Based on components of biological variation of the 
measurand
Model 3: Based on state of the art of the measurement, defined as 
the highest level of performance technically achievable
Adapted from Ref. [8].
Desirable standard
(satisfactory)
Minimum standard
(just satisfactory)
Optimum standard
(no need to improve)
Ideal
Unacceptable
Figure 1: Grading different quality levels of performance 
specifications.
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literature show that the current quality of laboratory per-
formance for many common analytes is probably not as 
satisfactory as expected when PS are selected according 
to the Milan models [15–17].
The Strategic Conference heritage
EFLM initiated Task and Finish Groups
The main outcome of the Strategic Conference was the 
creation of an EFLM Task Force (TF) on Performance 
Specifications in Laboratory Medicine (TF-PS). Under the 
TF-PS, five Task and Finish Groups (TFG) were established 
dealing with the main topics of the conference [7]. Accord-
ing to the EFLM policy, TFG are expected to complete their 
deliverables within 2  years. In this report, we highlight 
their major accomplishments.
The TFG on Allocation of Laboratory Tests to Differ-
ent Models for Performance Specifications (TFG-DM) has 
worked on the criteria for assigning different measurands 
to each of the three Milan models [18]. The work done by the 
TFG-DM represents a fundamental step towards propos-
ing practical principles for how to allocate measurands to 
different models. These principles will allow evaluations 
and clear indications for improvement; indeed, not all the 
PS will be immediately reachable, but they will highlight 
which limitations of the current technology should be pri-
oritized and solved.
The model 1 (“outcome-based PS”) should be applied 
when the measurand has a central and well-defined role 
in the decision making of a specific disease or a given 
clinical situation and test results should be interpreted 
through established decision limits. In other words, the 
test results should directly influence the outcome for 
the patient or society. For the optimal application of this 
model, the measurement should be standardized, so it 
is possible to define a common, method-independent 
threshold and consequently the impact of the measure-
ment error in terms of clinical misclassification [19]. HbA1c 
represents a good example. As in the Diabetes Control 
and Complications Trial (DCCT), patients in poor glycemic 
control had HbA1c concentrations >64  mmol/mol, while 
those in good glycemic control had values <53 mmol/mol, 
it can be estimated that, to properly classify an individual 
with an HbA1c value of 58.5 mmol/mol, the measurement 
error should not exceed ±5.5 mmol/mol, amounting to a 
relative total error (TE) of ±9.4% (5.5/58.5) [20–22]. Indeed, 
if the measurement error is greater, a patient with an 
HbA1c of 58.5 mmol/mol could be randomly misclassified 
into both glycemic control categories (good or poor) and 
this obviously would not be acceptable.
The model 2 (“biological variability-based PS”) should 
be applied when the measurand is in a “steady state” 
status when a subject is in good health. The TFG-DM rec-
ognizes these conditions as: (a) a situation where a meas-
urand has to be kept at a certain concentration level in 
the blood otherwise the body will suffer showing symp-
toms (the measurands is under strict homeostatic control, 
e.g. plasma ions); and (b) a situation where a measurand 
has de facto a stable concentration, but deviations from 
this concentration will not in itself cause symptoms (e.g. 
plasma metabolites, such as urate and creatinine). For 
measurands not in “steady state” (e.g. urinary analytes 
for which the concentrations vary to maintain the corre-
sponding plasmatic concentrations stable, compensating 
for dietary provision, water supplementation or loss, etc.), 
this model is more difficult to apply.
Finally, when a measurand cannot be placed in either 
model 1 or in model 2, it can be placed in model 3 (“state 
of the art-based PS”). This model can be temporarily used 
also for those measurands still waiting for the definition 
of outcome-based PS or while waiting for robust biological 
variability data.
There is a very wide variation in the analytical PS 
being used by EQAS providers, which adds further confu-
sion to an already difficult situation [23]. Why are the PS 
in EQAS so different? Because they mean different things 
in different programs. In general, if PS have regulatory 
impact, they are looser; if PS have aspirational inten-
tion of quality improvement, they may be tighter. Differ-
ent EQAS may also have different PS dependent on the 
analytical quality already present in the laboratories of 
their participants. Therefore, a harmonization through 
a collaborative effort, starting from clear definitions of 
elements to describe PS in EQAS, is needed. The TFG on 
Performance Specifications for EQAS (TFG-PEQAS) has 
identified six basic elements that need to be considered: 
(a) the nature of the EQAS material, including its commut-
ability, which may affect the result interpretation; (b) the 
procedure used to assign the target value; (c) the data set 
to which PS are applied; (d) the analytical property being 
assessed (i.e. TE, bias, imprecision); (e) the rationale for 
the selection of the PS; and (f) type(s) of model used to 
set PS [24].
For result interpretation in EQAS, there can be different 
types of analytical PS, depending on the number of repli-
cates of each EQAS sample performed by the participants. 
If participants measure in singlicate, a TE specification is 
needed (when only a single measurement is performed, 
the result includes effects of both bias and imprecision 
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errors and these cannot therefore be separated). If EQAS 
ask for multiple measurements of the same sample, a bias 
as well as an imprecision specification can be used for 
judgement of an EQAS result, providing that the scheme is 
also able to estimate the random component of the meas-
urement uncertainty of individual participants.
The TFG-PEQAS has recommended the use of one of 
the PS models from the Milan conference [24]. In agree-
ment with Infusino et al. [25], the addition of PS derived 
from Milan models to the EQAS categorization previously 
published by Miller et  al. [26] as criteria to evaluate the 
performance of laboratories participating to EQAS should 
be promoted. Miller’s categories 1 and 2, which fulfil the 
metrological requirements (commutable samples, value-
assigned with reference measurement procedure), should 
be each split in two sub-categories: 1/2A, in which Milan 
models 1 and 2 for PS are applied, and 1/2B, in which other 
low-order models to establish PS are employed [25]. As 
initial steps, the TFG-PEQAS encourages EQAS organizers 
to provide structured descriptions of PS and to review PS 
providing their rationale; in a more consolidated manner, 
they recommend developing common EQAS PS through a 
collaborative process and using relevant Milan model(s), 
in order to support uniform performance and high quality 
in the total examination process [24].
The Milan conference revitalized the TE vs. measure-
ment uncertainty discussion [9, 27]. If TE is still useful 
in evaluating single EQAS results, there is also a need 
to look carefully to the measurement uncertainty as 
this helps very much in the identification of important 
sources of bias [1, 28]. These concepts were taken forward 
by the TFG on Total Error (TFG-TE) established after the 
conference, commissioned with exploring, developing 
and coming up with a proposal for how to correctly use 
the TE concept and how to possibly combine PS for bias 
and imprecision in a more scientifically sound way. The 
TFG-TE has recalled criticisms to the conventional biolog-
ical variability model for deriving allowable TE to be used 
in assessing quality of laboratory measurements [29]. 
Using this approach that includes summing of mutual 
exclusive terms, an overestimation of the permissible TE 
was demonstrated [30]. An alternative model, in which 
the maximum permissible bias and imprecision are inter-
related and described in a curve and the permissible TE 
calculated from each point of the graph, has therefore to 
be considered to give a more realistic description of the 
permissible TE [31].
We already mentioned the need, recognized during 
the Strategic Conference, to improve information on the 
biological variability of laboratory analytes by apply-
ing more stringent criteria in the selection and review of 
available studies [11]. A dedicated TFG on Biological Vari-
ation Database (TFG-BVD) was established with the final 
aim to generate an EFLM biological variation database 
only including high quality studies and updated data after 
a careful appraisal by a very detailed checklist including 
14 items. Structured searches for biological variability 
studies have been performed by four different subgroups 
for lipids, enzymes, metabolites and kidney-related ana-
lytes. Papers are categorized as A, B, C and D, depending 
on their methodological quality, with category A papers 
indicating high quality and D poor quality [32]. The data-
base, hosted on the EFLM website, is currently under 
development and will also include derived PS for bias and 
imprecision of different measurands.
After the 1999 Stockholm Conference, much evidence 
was collected on the frequency and partition of errors in 
laboratory medicine and the vulnerability of both pre- and 
post-analytical phases has been highlighted as well as 
the risk for quality and patient safety [33]. Consequently, 
criteria for setting and harmonization of extra-analytical 
quality indicators have been developed and data collected 
[34]. This, in turn, should provide the premise to define 
reliable PS for the extra-analytical phases (Figure  2) 
[35,  36]. This was indeed the term of reference assigned 
to the TFG on Performance Specifications for the Extra- 
Analytical Phases (TFG-PSEP) [37].
According to the Milan consensus statement, in 
principle PS for extra-analytical phases should follow 
the same models as for analytical PS [8]. It is however 
difficult to apply model 2 to extra-analytical phases, 
so models 1 and 3 are therefore more usable. The TFG-
PSEP has recognized that PS based on a reliable state-
of-the-art, defined on surveyed quality indicator data, is 
the most feasible and attainable criterion to be quickly 
applicable [38]. The TFG-PSEP has agreed in fixing the 
limits for evaluation of the quality of laboratory extra-
analytical performance at the 25th and 75th percentile 
of the distribution of data collected on extra-analytical 
quality indicators by the IFCC Working Group on Labora-
tory Error and Patient Safety. The performance of indi-
vidual laboratories for each indicator is then classified 
according to following three quality levels in order to 
Figure 2: Proposed roadmap to define performance specifications 
in extra-analytical phases.
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allow laboratories to evaluate how they are placed in 
comparison with other laboratories and if improvement 
actions are needed [38]:
 – individual results <25th percentile of value distribu-
tion: high quality performance,
 – individual results between 25th and 75th percentile of 
value distribution: medium quality performance,
 – individual results >75th percentile of value distribu-
tion: low quality performance.
It has been proposed that at the end of each year of 
 collection, quality indicator data from participating lab-
oratories will be processed and analyzed, so allowing 
the update of the 25th and 75th percentiles to be used 
as PS for the following year. However, this will happen 
only if the average performance of all participants is 
improving.
Stimulating studies using Milan models to 
obtain PS
After the Milan conference, much work has been per-
formed to produce high quality data that can be used to 
set PS using the different models.
Difficulties in directly connecting laboratory testing 
to clinical outcomes are well known [39]. For this reason, 
defining PS using “indirect” outcome data (i.e. Milan 
model 1b) can be easier. Horvath et  al. [40] have thor-
oughly described the prerequisites to obtain this informa-
tion. Using model 1b, some recent studies have shown the 
clinical effects of varying analytical performance of some 
important tests, present in the model 1 list compiled by 
the TFG-DM [18].
Langlois et  al. [41] have performed a simulation 
study showing the clinical impact of some analytical bias 
caused by hypertriglyceridemia on commercial assays 
for direct measurements of HDL and LDL cholesterol. 
For instance, considering HDL cholesterol and its use as 
risk multiplier in the systematic coronary risk evaluation 
(SCORE) prediction model estimating 10-years risk of car-
diovascular mortality [42], when the two assays showing a 
negative bias of ~20% at serum triglyceride concentration 
~6.8 mmol/L were used, SCORE of 4% in male individu-
als were falsely brought to a value >5% in approximately 
2/3 of subjects (Table 2) [41]. In these cases, clinicians may 
wrongly modify treatment from lifestyle changes alone to 
drug therapy.
Given their clinical importance, cardiac troponins are 
one of the first biomarkers for which PS has been defined 
in terms of allowable misclassification rates [43]. Perform-
ing duplicate measurements, Sheehan et  al. [44] calcu-
lated how many times the result of the second replicate 
fell in a different diagnostic group, so that defining the 
percentage of misclassified patients with suspected acute 
myocardial infarction (AMI) based on assay imprecision. 
Very recently, Lyon et  al. [45] have applied a simulation 
model for estimating the misclassification rate of patients 
with suspected AMI when a highly sensitive troponin 
I assay in conjunction with its 99th percentile limit is 
employed. For example, a false positive rate of ~1% was 
obtained when both bias and imprecision of measure-
ments were kept around 10%.
As plasma glucose plays a relevant role in diagnosis 
of diabetes and its values are used to define glycemic-
related conditions, the outcome-based model should be 
preferred to derive PS for its measurement. By the way, 
Horvath et  al. [40] stated that studies investigating the 
direct impact of performance of laboratory tests on clini-
cal outcome are not necessary when: a) the clinical deci-
sions associated with the test results are well defined, 
b) evidence about the diagnostic accuracy of the test 
to classify patients for these clinical decisions is avail-
able and is generalizable to the patient population, and 
c) the consequences of correct/incorrect classification 
are established. As all these conditions are clearly ful-
filled by plasma glucose testing, model 1b can be safely 
adopted. Hyltoft Petersen pioneered the topic simulating 
Table 2: Clinical impact of biased HDL cholesterol-risk multipliers, simulated in men with initial SCORE of 4%. 
Direct method  Laboratories, n  HDL cholesterol median (range), mmol/L  Mean bias in the hyper­
triglyceridemic samplea
  SCORE >5%, n (%)
Reference   1  1.08 [HDL multiplier, 1; SCORE = 4%]   0%  −
Abbott   18  1.06 (0.98–1.10)   −2.8%  0
Beckman   39  1.00 (0.79–1.17)   −6.5%  2 (5%)
Olympus   8  0.98 (0.92–1.03)   −7.4%  0
Roche   113  0.87 (0.68–1.25)   −19.4%  71 (63%)
Siemens   14  0.79 (0.62–1.20)   −22.2%  10 (71%)
Adapted from Ref. [41]. SCORE, Systematic Coronary Risk Evaluation. aTriglyceride concentration, 6.78 mmol/L.
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the influence of analytical bias and imprecision of fasting 
plasma glucose measurement on the misclassification of 
healthy subjects as diabetics (false positives) and of dis-
eased subjects as healthy (false negatives) [46]. A simu-
lation based on the current definition of impaired fasting 
glucose (IFG) status (i.e. fasting glucose between 6.1 and 
6.9 mmol/L) has been recently done by Pasqualetti et al. 
[47]. They estimated that to properly classify an individual 
with a fasting plasma glucose of 6.5 mmol/L as IFG, the 
measurement error should not exceed ±6.15% (0.4/6.5). 
Indeed, if the measurement error is greater, a subject with 
a fasting glucose of 6.5 mmol/L could be randomly classi-
fied as either healthy or diabetic and this obviously would 
not be acceptable [47]. In a simulation analysis, a +6.15% 
error in plasma glucose measurement resulted in 7.7% 
of IFG subjects misdiagnosed as diabetes and 18.1% of 
healthy individuals classified as IFG. Conversely, a −6.15% 
error implied the shift of 6.2% subjects from diabetes to 
IFG category and of 12.6% IFG subjects to healthy group 
[48]. Interestingly, the authors showed the similarity of 
PS derived from the proposed model 1b approach and PS 
obtained by model 2 (i.e. biological variability-based), 
confirming the equivalence of the two models advocated 
by the Strategic Conference when measurands, such as 
fasting plasma glucose, with well-defined biological and 
clinical characteristics are considered [47].
The need to improve the biological variability studies 
has been already mentioned [12]. To this aim, the EFLM 
Working Group on Biological Variation (WG-BV) is working 
to a European project using a biobank of samples from 
91 healthy subjects to be used to produce high quality data 
[49]. The WG-BV has recently published biological variabil-
ity data for nine enzymes and creatinine in serum [50, 51]. 
A preliminary report is also available for serum ions [52]. 
Importantly, the obtained intra-individual CVs in these very 
strictly controlled studies are basically lower than those 
reported in the database available online [53]. This may 
translate in more stringent analytical PS, when derived 
using Milan model 2, than previously accounted for.
Conclusions
This paper presents an update of the activities initiated 
or stimulated after the EFLM Strategic Conference, held 
in Milan less than 3  years ago. Concepts about PS for 
EQAS, which measurands should use which models to 
set PS and how to set PS for the extra-analytical phases, 
together with the need for more quality data on biological 
variation and for further discussion about the TE concept 
were debated. In principle, the concepts here reported 
should be employed for all measurands used in the clini-
cal setting. It is expected that this work will now be taken 
forward, possibly by consolidating some of these activities 
in a permanent structure within EFLM. The EFLM Execu-
tive Board is discussing how to carry on the issue.
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